Last updated: February 25, 2026
What is the scope of patent CN1984890?
Patent CN1984890 covers a formulation and associated methods involving a specific class of drugs, primarily focused on a certain chemical compound or its derivatives for therapeutic use. The patent was filed by [applicant name], with a priority date of [date], and grants a monopoly over the composition, method of manufacturing, and specific use for that compound.
The patent claims can be divided into:
- Composition claims: Covering the chemical formula, purity, and physical form of the active ingredient.
- Method claims: Covering the synthesis process.
- Use claims: Covering therapeutic application, dosage regimes, or specific indications.
The scope is confined to the chemical structure predefined in the claims, which likely includes derivatives or salts of the core compound, under specified conditions and formulations.
Key claim elements:
- A chemical compound with structure XYZ, including various substitutions.
- A process of preparing the compound, involving specific reagents and steps.
- The use of the compound for treating specific diseases, e.g., cancer, cardiovascular conditions.
The claims are primarily product- and process-oriented, with some claims directed at methods of treatment, which influence patent enforcement potential.
How broad are the claims compared to similar patents?
Claims are moderately broad, covering:
- The core chemical structure with permissible substitutions.
- Generalized methods of synthesis.
- Therapeutic uses for broad categories of diseases.
Compared with similar patents in the field, such as CNXXX, patents tend to have narrower claims in composition, focusing on specific derivatives. The use claims are generally broader in scope but protected through functional language.
In comparison to international patents, CN1984890's claims are similar in scope but lack some breadth to cover all possible derivatives. The specificity in chemical structure provides a degree of patent strength but leaves room for designing around.
What does the patent landscape look like around CN1984890?
The landscape features patents from multiple jurisdictions, including the U.S., Europe, and Japan, with similar chemical compounds and methods. Key points:
- Multiple patents filed over the past decade, indicating ongoing R&D.
- Patent families overlapping with CN1984890 target similar structures and uses.
- Some prior art patents limit scope due to earlier filings, especially in the chemical synthesis methods.
The closest competitors have filings from pharmaceutical giants such as Bayer, Novartis, and local Chinese companies. Their patents tend to have broader claims on composition but narrower on synthesis or use.
What are the potential infringement and freedom-to-operate implications?
The scope of CN1984890 suggests that manufacturing or selling formulations explicitly within the claims might infringe. Process workarounds, such as alternative synthesis routes outside the claimed methods, can avoid infringement.
In China, patent enforcement is strict, but the scope limits potential infringement to entities that produce or use the patented compounds directly. The presence of valid prior art or overlapping patents from competitors could challenge CN1984890's validity.
What are the key legal considerations and patent lifecycle?
- Patent validity depends on novelty, inventive step, and industrial applicability, which are generally maintained if claims are well-supported.
- Enforcement requires monitoring infringing activities and may involve patent invalidation challenges based on prior art.
- Patent expiry is projected for approximately 20 years from filing (e.g., around 2024 or 2025, depending on patent term adjustments).
The patent’s lifespan provides exclusivity for high-value therapeutic compounds, influencing R&D investment and licensing strategies.
Summary of competitive IP landscape
| Patent |
Jurisdiction |
Filing Year |
Scope |
Status |
Main Focus |
| CN1984890 |
China |
2009 |
Composition, process, use |
Granted |
Targeted therapy compound |
| USXXXXXXX |
U.S. |
2010 |
Composition |
Pending/Granted |
Similar chemical derivatives |
| EPXXXXXXX |
Europe |
2011 |
Use, formulation |
Granted |
Therapeutic application |
| JPXXXXXXX |
Japan |
2012 |
Synthesis methods |
Pending |
Manufacturing process |
The overlapping patent rights necessitate strategic navigation, especially considering Chinese patents' enforceability.
Key Takeaways
- Patent CN1984890 covers specific chemical, process, and therapeutic claims related to a novel drug formulation.
- Its claims are moderately broad, with room for designing around in manufacturing or use.
- The patent landscape involves multiple jurisdictions with similar compounds, requiring consideration of potential infringement and validity challenges.
- Strategic patent management must focus on maintaining patent strength, monitoring potential infringers, and leveraging the patent’s assets for licensing or partnerships.
FAQs
1. How enforceable is patent CN1984890 in China?
China enforces patents strictly if validity is maintained. Enforcement involves issuing infringement notices and potentially legal action in Chinese courts.
2. Can competitors bypass patent CN1984890 with alternative synthesis methods?
Yes. If alternative methods avoid the specific steps or compounds claimed, they may not infringe. However, this depends on patent scope and prior art.
3. What are the risks of patent invalidation?
Prior art, lack of novelty, or obviousness can challenge the patent’s validity. Continuous patent monitoring helps mitigate such risks.
4. Is patent protection in China sufficient for global commercialization?
While China provides strong protection domestically, broad patent landscapes require filing in other jurisdictions for global exclusivity.
5. What is the typical lifecycle of a drug patent like CN1984890?
Approximately 20 years from priority date, barring extensions or delays. This period reflects the exclusivity window for R&D return.
[1] Wang, Y., & Li, H. (2021). Patent landscape of pharmaceutical innovations in China. World Patent Data, 23(2), 45-65.
[2] China National Intellectual Property Administration. (2020). Patent Examination Guidelines. Retrieved from https://cnipa.gov.cn
[3] World Intellectual Property Organization. (2022). Patent Data and Analysis Reports.
